Etripamil

Etripamil
Clinical data
Trade names	Cardamyst
Other names	MSP-2017
AHFS/Drugs.com	Cardamyst
License data	US DailyMed: Etripamil ;
Routes of; administration	Intranasal
Drug class	Calcium channel blocker
ATC code	C08DA03 ( WHO );
Legal status
Legal status	US: ℞-only ;
Identifiers
CAS Number	1593673-23-4 ; 2560549-35-9 ;
PubChem CID	91824132 ;
DrugBank	DB12605 ;
ChemSpider	44208826 ;
UNII	S82A18Y42P ; 9TA9AC3H8Z ;
KEGG	D10932 ;
ChEMBL	ChEMBL3707312 ;
Chemical and physical data
Formula	C27H36N2O4
Molar mass	452.595 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES COC(=O)C1=CC(CCN(C)CCC[C@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)=CC=C1;
	InChI InChI=1S/C27H36N2O4/c1-20(2)27(19-28,23-11-12-24(31-4)25(18-23)32-5)14-8-15-29(3)16-13-21-9-7-10-22(17-21)26(30)33-6/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t27-/m0/s1; Key:VAZNEHLGJGSQEL-MHZLTWQESA-N; Key:JHOAIMAMBNLIMD-YCBFMBTMSA-N;

Last updated December 18, 2025

Etripamil, sold under the brand name Cardamyst, is a medication used for the treatment of paroxysmal supraventricular tachycardia.^[1] It is a calcium channel blocker.^[1] It is used as a nasal spray.^[1]

Medical uses

Etripamil is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm.^[1]^[3]^[4]

Pharmacology

Mechanism of action

Etripamil is a voltage-dependent L-type calcium channel inhibitor.^[3]

Society and culture

Legal status

Etripamil was approved for medical use in the United States in December 2025.^[2]

Names

Etripamil is the international nonproprietary name.^[5]

Etripamil is sold under the brand name Cardamyst.^[1]

References

1 2 3 4 5 6 "Cardamyst (etripamil) nasal spray" (PDF). Milestone Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. December 2025.
1 2 "Milestone Receives FDA Approval of Cardamyst (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)" (Press release). Milestone Pharmaceuticals. 13 December 2025. Retrieved 16 December 2025– via GlobeNewswire News Room.
1 2 Calvert P, Gupta D (2024). "Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia". Future Cardiology. 20 (3): 163–170. doi: 10.1080/14796678.2024.2342651 . PMC 11216497 . PMID 38717391.
↑ Jha M, Song D, Kung A, Lo S, Sacher A, Ang SP, et al. (May 2025). "Efficacy and Safety of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia: Meta-Analysis of Randomized Controlled Trials". Journal of Clinical Medicine. 14 (11): 3720. doi: 10.3390/jcm14113720 . PMC 12155871 . PMID 40507484.
↑ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl: 10665/331046 .

External links

Clinical trial number 03464019 for "Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). (NODE-301)" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[Cardamyst_FDA_label-1] 1 2 3 4 5 6 "Cardamyst (etripamil) nasal spray" (PDF). Milestone Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. December 2025.

[Milestone_PR_20251213-2] 1 2 "Milestone Receives FDA Approval of Cardamyst (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)" (Press release). Milestone Pharmaceuticals. 13 December 2025. Retrieved 16 December 2025– via GlobeNewswire News Room.

[Calvert_2024-3] 1 2 Calvert P, Gupta D (2024). "Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia". Future Cardiology. 20 (3): 163–170. doi: 10.1080/14796678.2024.2342651 . PMC 11216497 . PMID 38717391.

[Jha_2025-4] Jha M, Song D, Kung A, Lo S, Sacher A, Ang SP, et al. (May 2025). "Efficacy and Safety of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia: Meta-Analysis of Randomized Controlled Trials". Journal of Clinical Medicine. 14 (11): 3720. doi: 10.3390/jcm14113720 . PMC 12155871 . PMID 40507484.

[5] World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl: 10665/331046 .

[1]

[2]

[3]

[4]

[5]